.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Queensland Health
Dow
US Department of Justice
Chubb
UBS
Covington
Fish and Richardson
US Army
McKesson

Generated: September 24, 2017

DrugPatentWatch Database Preview

Purdue Pharma Company Profile

« Back to Dashboard

What is the competitive landscape for PURDUE PHARMA, and what generic alternatives to PURDUE PHARMA drugs are available?

PURDUE PHARMA has nine approved drugs.

There are seventy-two US patents protecting PURDUE PHARMA drugs.

There are nine hundred and thirty-seven patent family members on PURDUE PHARMA drugs in fifty-three countries.

Summary for Applicant: Purdue Pharma

Patents:72
Tradenames:9
Ingredients:9
NDAs:9
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-007Nov 20, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-001Nov 20, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-005Nov 20, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Purdue Pharma Lp
OXYCONTIN
oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022272-007Apr 5, 2010RXYesNo► Subscribe► SubscribeY ► Subscribe
Purdue Pharma Lp
TARGINIQ
naloxone hydrochloride; oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL205777-001Jul 23, 2014DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Purdue Pharma Lp
OXYCONTIN
oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022272-004Apr 5, 2010RXYesNo► Subscribe► Subscribe► Subscribe
Purdue Pharma Lp
OXYCONTIN
oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022272-004Apr 5, 2010RXYesNo► Subscribe► SubscribeY ► Subscribe
Purdue Pharma Lp
OXYCONTIN
oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022272-004Apr 5, 2010RXYesNo► Subscribe► SubscribeYY ► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-007Nov 20, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Purdue Pharma Lp
PALLADONE
hydromorphone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021044-003Sep 24, 2004DISCNNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Purdue Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Purdue Pharma Lp
MS CONTIN
morphine sulfate
TABLET, EXTENDED RELEASE;ORAL019516-004Jan 16, 1990► Subscribe► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-007Nov 20, 2014► Subscribe► Subscribe
Purdue Pharma Lp
PALLADONE
hydromorphone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021044-004Sep 24, 2004► Subscribe► Subscribe
Purdue Pharma Lp
PALLADONE
hydromorphone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021044-004Sep 24, 2004► Subscribe► Subscribe
Purdue Pharma Lp
PALLADONE
hydromorphone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021044-001Sep 24, 2004► Subscribe► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-004Nov 20, 2014► Subscribe► Subscribe
Purdue Pharma Lp
BUTRANS
buprenorphine
FILM, EXTENDED RELEASE;TRANSDERMAL021306-003Jun 30, 2010► Subscribe► Subscribe
Purdue Pharma Lp
CHIROCAINE
levobupivacaine hydrochloride
INJECTABLE;INJECTION020997-002Aug 5, 1999► Subscribe► Subscribe
Purdue Pharma Lp
CHIROCAINE
levobupivacaine hydrochloride
INJECTABLE;INJECTION020997-003Aug 5, 1999► Subscribe► Subscribe
Purdue Pharma Lp
PALLADONE
hydromorphone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021044-002Sep 24, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PURDUE PHARMA drugs

Drugname Dosage Strength Tradename Submissiondate
buprenorphine
Transdermal System15 mcg/hr
BUTRANS
12/16/2013
buprenorphine
Transdermal System5 mcg/hr, 10 mcg/hr, and 20 mcg/hr
BUTRANS
6/6/2013
zolpidem tartrate
Sublingual Tablets1.75 mg and 3.5 mg
INTERMEZZO
4/10/2012
tramadol hydrochloride
Extended-release Tablets100 mg, 200 mg and 300 mg
RYZOLT
6/18/2009
oxycodone hydrochloride
Extended-release Tablets15 mg
OXYCONTIN
2/15/2007
oxycodone hydrochloride
Extended-release Tablets30 mg and 60 mg
OXYCONTIN
1/3/2007

Non-Orange Book Patents for Purdue Pharma

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,514,100Controlled release hydrocodone formulations► Subscribe
8,114,383Abuse-proofed dosage form► Subscribe
9,693,961Pharmaceutical formulation containing gelling agent► Subscribe
9,044,435Pharmaceutical formulation containing gelling agent► Subscribe
9,179,825Positioning system for manipulating a channel within a medical device► Subscribe
8,822,6878a,14-dihydroxy-7,8-dihydrocodeinone► Subscribe
9,034,376Pharmaceutical formulation containing gelling agent► Subscribe
7,332,182Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant► Subscribe
7,157,103Pharmaceutical formulation containing irritant► Subscribe
8,017,148Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Purdue Pharma Drugs

Country Document Number Estimated Expiration
Germany502004010368► Subscribe
Hong Kong1138498► Subscribe
Israel240001► Subscribe
Japan4897930► Subscribe
Germany09003265► Subscribe
Japan5202963► Subscribe
African Regional IP Organization (ARIPO)3815► Subscribe
Israel131561► Subscribe
Israel213889► Subscribe
South Korea100930730► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Purdue Pharma Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013000082Germany► SubscribePRODUCT NAME: KOMBINATION VON OXYCODON ALS KOMPONENTE A UND NALOXON ALS KOMPONENTE B IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: 64537.00.00 64538.00.00 64540.00.00 64541.00.00 73083.00.00 73084.00.00 73085.00.00 73086.00.00 20060530
00152Netherlands► SubscribePRODUCT NAME: TRAMADOLI HYDROCHLORIDUM EN PARACETAMOLUM; NAT. REGISTRATION NO/DATE: RVG 28113 20030115; FIRST REGISTRATION: 359 228-3 2002050405
292Luxembourg► SubscribePRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
00714Netherlands► SubscribePRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718
2013 00052Denmark► SubscribePRODUCT NAME: KOMBINATION AF OXYCODON SOM KOMPONENT A OG NALOXON SOM KOMPONENT B, HERUNDER OXYCODONHYDROCHLORID OG NALOXONHYDROCHLORIDDIHYDRAT; NAT. REG. NO/DATE: 43673, 43674 20081117; FIRST REG. NO/DATE: DE 64537.00.00, 64538.00.00, 64540.00.00, 64541.00.00 20060530
636Luxembourg► SubscribePRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
2015 00004Denmark► SubscribePRODUCT NAME: ZOLPIDEM OG FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER ZOLPIDEMTARTRAT; NAT. REG. NO/DATE: 47607 OG 47608 20120719; FIRST REG. NO/DATE: (B BE424286 OG BE424295 20120718
00619Netherlands► SubscribePRODUCT NAME: EEN COMBINATIE VAN OXYCODON ALS COMPONENT A EN NALOXON ALS COMPONENT B IN ALLE VORMEN ZOALS DEZE DOOR HET BASIS OCTROOI ONDER BESCHERMING WORDEN GESTELD; REGISTRATION NO/DATE: 64537.00.00 64538.00.00 64540.00.00 64541.00.00 20060530
2015000006Germany► SubscribePRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718
C/GB04/012United Kingdom► SubscribePRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Healthtrust
Accenture
Argus Health
US Department of Justice
Fish and Richardson
Fuji
Novartis
Cantor Fitzgerald
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot